Syndax's Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20.
Syndax Pharmaceuticals Inc (SNDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 8,520,000 | $79,789,800 | 8.59% | |
| 2. | Eversept Partners Kamran Moghtaderi | 4,065,355 | $38,072,050 | -4% | 3.5% |
| 3. | StemPoint Capital Michelle Ross | 2,372,634 | $22,219,717 | +49% | 7.13% |
| 4. | Point72 Asset Management Steve Cohen | 2,127,467 | $19,923,729 | -47% | 0.04% |
| 5. | Catalio Capital Management George Petrocheilos And R. Jacob Vogelstein | 2,104,512 | $19,708,755 | +22% | 4.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 3,000 | $0.00 | 93,746 | 2025-05-19 | Filing | |
| $9.00 | 11,765 | $105,826.18 | 35,165 | 2025-05-16 | Filing | |
| $8.99 | 5,000 | $44,950.00 | 79,000 | 2025-05-19 | Filing | |
| $9.11 | 10,000 | $91,120.00 | 100,000 | 2025-05-19 | Filing | |
| $20.03 | 1,250 | $25,037.25 | 52,623 | 2024-06-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.41 | 157,307 | $2,582,021.37 | 298,661 | 2025-09-08 | Filing | |
| $15.84 | 19,200 | $304,170.24 | 191,763 | 2025-08-18 | Filing | |
| $15.54 | 19,200 | $298,408.32 | 191,763 | 2025-08-15 | Filing | |
| $14.19 | 19,200 | $272,520.96 | 191,763 | 2025-08-14 | Filing | |
| $9.29 | 1,296 | $12,033.36 | 92,450 | 2025-07-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,784,139 | $27,448,979 | 0.04% | |
| 2. | 83,207 | $1,280,140 | 0% | |
| 3. | 28,833 | $443,596 | 0.04% | |
| 4. | 185 | $2,846 | 0% | |
| 5. | 37 | $569 | 0% |
News See All
10 Best Stocks to Buy Under $20
On September 16, Ali Dibadj, Janus Henderson Investors CEO, joined 'Squawk Box' on CNBC to discuss the latest market trends and suggest that small and mid-cap stocks have enormous potential to deliver...
Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals
Headquartered in Massachusetts, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage oncology company engaged in developing novel combination therapies for cancer.
BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best small cap stocks with biggest upside potential.
9 Best Small Cap Stocks with Biggest Upside Potential
On August 14, Jonathan Krinsky of BTIG, joined 'Closing Bell' on CNBC to discuss whether the recent rally in small cap stocks is sustainable.
11 Best Short Squeeze Stocks to Buy Now
The latest U.S. tariff wave has created a suitable environment where short squeeze investments will thrive.
FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc.
11 Best Short-Term Stocks to Invest in
The latter half of the 2025 market is caught between conflicting signals.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Second Quarter 2025 Earnings Conference Call. Today's call is being recorded.
Syndax's Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts.
Hedge Fund Resource Center Billionaire Hedge Funds
